Production (Stage)
BioCryst Pharmaceuticals, Inc.
BCRX
$10.59
$0.201.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.67% | 36.00% | 29.92% | 24.65% | 22.68% |
| Total Other Revenue | -- | -28.18% | -45.26% | -63.58% | -53.71% |
| Total Revenue | 41.67% | 36.00% | 29.92% | 24.65% | 22.68% |
| Cost of Revenue | -15.81% | -13.69% | -11.85% | -13.41% | -11.71% |
| Gross Profit | 129.78% | 129.80% | 131.86% | 146.35% | 204.60% |
| SG&A Expenses | 28.46% | 24.69% | 25.12% | 26.59% | 30.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.83% | 5.36% | 5.52% | 4.32% | 5.68% |
| Operating Income | 139.09% | 97.43% | 66.67% | 50.93% | 33.13% |
| Income Before Tax | 75.46% | 61.56% | 47.08% | 38.89% | 6.52% |
| Income Tax Expenses | 57,100.00% | 521.61% | -116.95% | -118.74% | -99.87% |
| Earnings from Continuing Operations | 74.37% | 60.77% | 47.61% | 39.88% | 7.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.37% | 60.77% | 47.61% | 39.88% | 7.81% |
| EBIT | 139.09% | 97.43% | 66.67% | 50.93% | 33.13% |
| EBITDA | 144.11% | 100.49% | 68.35% | 52.28% | 34.09% |
| EPS Basic | 75.80% | 63.50% | 51.58% | 43.50% | 11.89% |
| Normalized Basic EPS | 72.19% | 57.85% | 46.44% | 36.91% | 25.59% |
| EPS Diluted | 75.86% | 63.59% | 51.54% | 43.47% | 11.85% |
| Normalized Diluted EPS | 72.17% | 57.85% | 46.44% | 36.91% | 25.59% |
| Average Basic Shares Outstanding | 5.51% | 7.56% | 8.83% | 7.03% | 5.22% |
| Average Diluted Shares Outstanding | 6.33% | 7.56% | 8.83% | 7.03% | 5.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |